WCLC 2023
Related
BGB-16673 is an investigational chimeric degradation activating compound (CDAC) targeting BTK. Watch the mechanism of action video (MoA) to learn more.
Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.
View this interactive infographic to learn more about acquired BTK mutations that can result in drug resistance.
This book provides an overview of marginal zone lymphoma (MZL) for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the relapsed/refractory (R/R) setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.
This book offers the necessary information for patients diagnosed with follicular lymphoma (FL) to engage in meaningful conversations with their healthcare providers. It empowers them to make informed decisions about managing their condition. Download this e-book to provide your patients with a deeper understanding of their illness.